Sage CEO’s M&A chat­ter sparks a spike, and an awk­ward cor­rec­tion

Few biotech CEOs like to hype da­ta from tiny stud­ies quite as much as an en­thu­si­as­tic Jeff Jonas at Sage $SAGE. But on Thurs­day, he pumped it a lit­tle too hard.

Doni Bloom­field from Bloomberg taped him for a seg­ment on the Bay State Biotech Re­port in which he talked about SAGE-217’s shot at be­com­ing a “first-line” ther­a­py for de­pres­sion.

Not on­ly did the drug cut scores on de­pres­sion among se­vere­ly de­pressed peo­ple by 20%, he said, “there’s a good like­li­hood it will help peo­ple sleep.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.